Loading company…
Austin-based biotechnology company developing human enzyme therapeutics for rare genetic diseases and cancer.
Founded in 2013 and based in Texas, US, Spyre Theraputics, Inc. develops human enzyme therapeutics for rare genetic diseases and cancer. Its work also targets Inflammatory Bowel Disease, including ulcerative colitis and Crohn's disease, with monoclonal antibody candidates SPY001 and SPY002. As of July 2024 the company was led by CFO Scott Burrows and VP Corporate Controller Jonathan Campbell. Its stage is recorded as Public.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in